- Home
- GLQ vs COYA Comparison
GLQ vs COYA Comparison
Compare GLQ & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLQ
- COYA
- Stock Information
- Founded
- GLQ 2005
- COYA 2020
- Country
- GLQ United States
- COYA United States
- Employees
- GLQ N/A
- COYA N/A
- Industry
- GLQ Finance/Investors Services
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- GLQ Finance
- COYA Health Care
- Exchange
- GLQ Nasdaq
- COYA Nasdaq
- Market Cap
- GLQ 119.5M
- COYA 103.2M
- IPO Year
- GLQ N/A
- COYA 2022
- Fundamental
- Price
- GLQ $6.49
- COYA $6.05
- Analyst Decision
- GLQ
- COYA Strong Buy
- Analyst Count
- GLQ 0
- COYA 4
- Target Price
- GLQ N/A
- COYA $17.00
- AVG Volume (30 Days)
- GLQ 65.5K
- COYA 69.3K
- Earning Date
- GLQ 01-01-0001
- COYA 05-16-2025
- Dividend Yield
- GLQ 11.11%
- COYA N/A
- EPS Growth
- GLQ N/A
- COYA N/A
- EPS
- GLQ N/A
- COYA N/A
- Revenue
- GLQ N/A
- COYA $3,554,061.00
- Revenue This Year
- GLQ N/A
- COYA $94.45
- Revenue Next Year
- GLQ N/A
- COYA N/A
- P/E Ratio
- GLQ N/A
- COYA N/A
- Revenue Growth
- GLQ N/A
- COYA N/A
- 52 Week Low
- GLQ $5.13
- COYA $4.65
- 52 Week High
- GLQ $6.54
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- GLQ 62.75
- COYA 49.30
- Support Level
- GLQ $6.22
- COYA $5.77
- Resistance Level
- GLQ $6.12
- COYA $6.59
- Average True Range (ATR)
- GLQ 0.08
- COYA 0.54
- MACD
- GLQ 0.05
- COYA 0.01
- Stochastic Oscillator
- GLQ 87.84
- COYA 24.81
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.